Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01723709 · ClinicalTrials.gov registry record
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
A clinical trial of Multiple Sclerosis, sponsored by Duke University.
- Completed
- Registry status
- 973
- Enrollment target
- 5
- Study locations
NCT01723709: Completed study of Multiple Sclerosis, sponsored by Duke University.
NCT01723709 is a study of Multiple Sclerosis that has completed, run by Duke University. The registered enrollment target is 973 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (67% higher). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01723709, a study of Multiple Sclerosis, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 973 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this study is to enroll 1000 participants with a history of Multiple Sclerosis into the MURDOCK Study (Duke IRB Pro00011196) as well as into the Multiple Sclerosis Cohort study (Duke IRB Pro00023791). All 1000 participants will answer a 4-page questionnaire administered by a trained study coordinator which is designed to collect information on the participant's diagnosis of Multiple Sclerosis. The goal of the study is to seek genetic explanations for response to treatment, progression of the disease, and biomarker validation.
Primary Outcome
Biological material (serum, urine, whole blood and Paxgene RNA) collected in the MURDOCK Study(Pro00011196) will permit the initiation of a biomarker discovery project for all patients consented under the MS cohort protocol. Participants in this study will be followed for 5 years after consent with additional blood draws and questionnaires occurring biannually during this period.
Conditions Studied
Study Locations (5)
North Carolina
- Carolinas Medical Center Northeast Medical Arts Building - Concord
- Ada Jenkins Center - Davidson
- The Stedman Center on the Duke Center for Living Campus - Durham
- Kannapolis Internal Medicine - Kannapolis
- Raleigh Neurology Associates - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 973 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-05 |
What the finished NCT01723709 record still lists
NCT01723709 is an observational study that tracks outcomes without assigning an intervention. The registered 973 participants enrollment target is mid-sized for trials with a published cap, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT01723709 lists 5 locations in 1 state (North Carolina).
Frequently Asked Questions
What is clinical trial NCT01723709 about?
NCT01723709 is a clinical study titled "The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort". The goal of this study is to enroll 1000 participants with a history of Multiple Sclerosis into the MURDOCK Study (Duke IRB Pro00011196) as well as into the Multiple Sclerosis Cohort study (Duke IRB Pro00023791). All 1000 participants will answer a 4-page questionnaire administered by a trained stud...
What is the current status of trial NCT01723709?
This trial is currently completed. The enrollment target is 973 participants. The study started on 2010-06. Estimated completion is 2017-05.
What conditions does trial NCT01723709 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT01723709?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01723709 being conducted?
This trial has 5 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01723709's enrollment target sits among peer trials
973 30th of 315 higher than 286 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia